Work

Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Year: 2019

Type: article

Author: E. Rothschedl

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2976409616

FWCI:

Cites:

Cited by:

Related to: 10